Published in J Virol on October 01, 2001
Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol (2004) 1.37
Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev (2007) 1.31
Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother (2004) 1.23
Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol (2003) 1.15
GGA and Arf proteins modulate retrovirus assembly and release. Mol Cell (2008) 1.07
Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol (2003) 0.98
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob Agents Chemother (2005) 0.97
Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol (2004) 0.95
Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication. J Virol (2009) 0.94
Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance. J Virol (2007) 0.90
Refined study of the interaction between HIV-1 p6 late domain and ALIX. Retrovirology (2008) 0.89
Molecular characterization of the HIV-1 gag nucleocapsid gene associated with vertical transmission. Retrovirology (2006) 0.83
Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients. AIDS (2014) 0.83
Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain. J Virol (2015) 0.82
Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays. J Clin Microbiol (2010) 0.80
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother (2002) 0.79
Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG. AIDS Res Hum Retroviruses (2008) 0.78
The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility. Retrovirology (2016) 0.75
The PTAP sequence duplication in HIV-1 subtype C Gag p6 in drug-naive subjects of India and South Africa. BMC Infect Dis (2017) 0.75
Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent manner. PLoS One (2017) 0.75
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 11.22
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother (2000) 8.54
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J (2000) 6.26
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci U S A (2000) 4.19
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS (1993) 3.52
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol (1996) 3.39
Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1992) 3.23
Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses. J Virol (2000) 2.98
Inoculum effect. Rev Infect Dis (1989) 2.63
HIV treatment failure: testing for HIV resistance in clinical practice. Science (1998) 2.46
Site-directed mutations in Sindbis virus E2 glycoprotein's cytoplasmic domain and the 6K protein lead to similar defects in virus assembly and budding. Virology (1991) 2.14
Ubiquitin in retrovirus assembly: actor or bystander? Proc Natl Acad Sci U S A (2000) 2.08
Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat Struct Biol (1999) 2.00
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol (1999) 1.85
Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses (2000) 1.82
Centrifugal enhancement of retroviral mediated gene transfer. J Virol Methods (1995) 1.76
Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J Virol (1995) 1.45
Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS (2000) 1.42
Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1991) 1.33
Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation. J Gen Virol (1995) 1.29
Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. J Virol (1999) 1.23
Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J Virol (1998) 1.20
Intrapatient sequence variation of the gag gene of human immunodeficiency virus type 1 plasma virions. J Virol (1996) 1.16
Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein. J Biol Chem (1999) 1.11
Amplification of the ribonucleotide reductase small subunit gene: analysis of novel joints and the mechanism of gene duplication in vaccinia virus. Nucleic Acids Res (1989) 1.00
Role of the locus and of the resistance gene on gene amplification frequency in methotrexate resistant Leishmania tarentolae. Nucleic Acids Res (1999) 0.90
New antivirals - mechanism of action and resistance development. Curr Opin Microbiol (1998) 0.88
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol (1998) 6.59
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother (1994) 6.39
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 5.52
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Epidemiological basis for clinical diagnosis of childhood malaria in endemic zone in West Africa. Lancet (1991) 5.11
Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet (1993) 4.96
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med (1995) 4.10
Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors. Science (1999) 3.96
Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother (2000) 3.56
Localization of the heat shock-induced proteins in Drosophila melanogaster tissue culture cells. Dev Biol (1980) 3.51
Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet (1999) 3.43
Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors. Science (1999) 3.41
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
A novel insertion element from Mycobacterium avium, IS1245, is a specific target for analysis of strain relatedness. J Clin Microbiol (1995) 3.20
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther (2000) 3.14
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol (2001) 3.05
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother (1997) 3.05
Ultrastructural distribution of nuclear ribonucleoproteins as visualized by immunocytochemistry on thin sections. J Cell Biol (1984) 2.92
Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol (1996) 2.66
The ultrastructural visualization of nucleolar and extranucleolar RNA synthesis and distribution. Int Rev Cytol (1980) 2.62
Crystal structure of GyrA intein from Mycobacterium xenopi reveals structural basis of protein splicing. Nat Struct Biol (1998) 2.59
Vertical strabismus after cataract surgery. Ophthalmology (1996) 2.56
Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob Agents Chemother (1997) 2.53
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol (1999) 2.51
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48
HIV treatment failure: testing for HIV resistance in clinical practice. Science (1998) 2.46
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol (1997) 2.24
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis (2001) 2.24
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother (1995) 2.22
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
The release of cytochrome c from mitochondria during apoptosis of NGF-deprived sympathetic neurons is a reversible event. J Cell Biol (1999) 2.12
Dietetic guidelines on food and nutrition in the secondary prevention of cardiovascular disease - evidence from systematic reviews of randomized controlled trials (second update, January 2006). J Hum Nutr Diet (2006) 2.09
Ultrastructural analysis of transcription and splicing in the cell nucleus after bromo-UTP microinjection. Mol Biol Cell (1999) 2.08
Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother (1999) 2.02
Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax (2013) 2.02
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
[Cervical cancer screening. False negative smears]. Rev Med Suisse Romande (1997) 1.94
Localisation of rapidly and slowly labelled nuclear RNA as visualized by high resolution autoradiography. Exp Cell Res (1971) 1.90
Nosocomial outbreak of multiple bloodborne viral infections. J Infect Dis (2001) 1.89
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer (2013) 1.85
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS (1999) 1.85
Localization and characterization of newly synthesized nuclear RNA in isolate rat hepatocytes. Exp Cell Res (1976) 1.82
Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses (2000) 1.82
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS (2003) 1.76
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr (2001) 1.71
Immunodetection of poly(A) binding protein II in the cell nucleus. Exp Cell Res (1994) 1.67
Rapid and sensitive detection of enteroviruses in specimens from patients with aseptic meningitis. J Clin Microbiol (1996) 1.67
Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol (1998) 1.65
Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.65
Emergence delirium in a child given oral midazolam for conscious sedation. Ann Emerg Med (1994) 1.63
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet (1998) 1.62
Immunoelectron microscope visualization of nuclear ribonucleoprotein antigens within spread transcription complexes. J Cell Biol (1986) 1.62
Typing of Pneumocystis carinii f. sp. hominis by single-strand conformation polymorphism of four genomic regions. J Clin Microbiol (1997) 1.59
Electrostatic force microscopy on oriented graphite surfaces: coexistence of insulating and conducting behaviors. Phys Rev Lett (2006) 1.58
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther (2009) 1.57
Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy. AIDS (2001) 1.55
A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth (2011) 1.55
Clinical relevance of cytomegalovirus viraemia(*,†). HIV Med (2011) 1.55
Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. AIDS (2000) 1.53
Evaluation of the relatedness of strains of Mycobacterium avium using pulsed-field gel electrophoresis. Eur J Clin Microbiol Infect Dis (1995) 1.51
Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis (1990) 1.50
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med (1998) 1.50
Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science (1995) 1.48
[Clinical practice guideline based on the evidence for the management of sedoanalgesia in the critically ill adult patient]. Med Intensiva (2007) 1.48
Genotypic characterization of Mycobacterium avium strains recovered from animals and their comparison to human strains. Appl Environ Microbiol (1995) 1.47
Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism. J Virol (1996) 1.47
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS (1998) 1.46
The dental management of patients with natural rubber latex allergy. Br Dent J (1998) 1.44
Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS (2000) 1.44
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS (1999) 1.44
Nef enhances human immunodeficiency virus replication and responsiveness to interleukin-2 in human lymphoid tissue ex vivo. J Virol (1999) 1.43
[Post-exposure HIV prevention: eligibility of patients recently infected by sexual exposure]. Schweiz Med Wochenschr (1999) 1.40
Differential intraocular pressure in restrictive strabismus. Am J Ophthalmol (1991) 1.40
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clin Infect Dis (2016) 1.39
Use of buccal fat pad to repair intraoral defects: review of 30 cases. Br J Oral Maxillofac Surg (1997) 1.37
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis (2000) 1.37
Sexual transmission during the incubation period of primary HIV infection. JAMA (2001) 1.37
[The 2013 Seville Consensus Document on alternatives to allogenic blood transfusion. An update on the Seville Document]. Rev Esp Anestesiol Reanim (2013) 1.37
Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth (2008) 1.36
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (1999) 1.36
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther (2010) 1.36